You are here

Holly Soutter

Selected publication and patents

Lee KL, Ambler CM…Soutter HH, et al. Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design  J. Med. Chem. 2017 60(13):5521-5542

Cheng RKY, Fiez-Vandal C…Soutter HH, et al. Structural insight into allosteric modulation of protease-activated receptor 2. Nature. 2017 545:112-115.

Soutter HH, Paolo Centrella P, et al. Discovery of cofactor-specific, bactericidal Mycobacterium tuberculosis InhA inhibitors using DNA-encoded library technology. Proc. Natl. Acad. Sci. U.S.A. 2016 113(49):E7880-E7889.

Borhani DW, Sadhukhan R, Lacy SE, Soutter HH Anti-Il-12/Il-23 antibodies and uses thereof. 2012 PCT/US2012/020529


Holly Soutter, Ph.D.

Holly Soutter is associate director of biochemistry and biophysics within the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. Her research unit supports projects across multiple therapeutic areas to identify, validate, and mechanistically characterize potential small molecule therapeutics. Her team has expertise in multiple techniques including SPR, NMR, mass spectrometry, enzymology, and many others.

Soutter brings 15 years of experience in drug discovery and development to CDoT. She is co-inventor of multiple clinical candidates, and has co-authored more than 20 scientific publications. Before coming to the Broad in 2020, she led the biochemistry and biophysics group at Silicon Therapeutics, an immuno-oncology startup. She has extensive expertise in DNA-encoded library technologies, having worked at X-Chem for 6 years prior to joining Silicon.

She received her B.A. in chemistry from Hunter College, and her M.A. and Ph.D. in chemistry from Clark University.

Contact Holly Soutter via email at

February 2021